Therapy Detail

Therapy Name Galunisertib
Therapy Description

Galunisertib (LY2157299) is a TGFBR1 antagonist, which inhibits downstream signaling and may suppress tumor growth (PMID: 18039567).


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Galunisertib LY2157299 TGFBR1 inhibitor 12 Galunisertib (LY2157299) is a TGFBR1 antagonist, which inhibits downstream signaling and may suppress tumor growth (PMID: 18039567).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown pancreatic cancer not applicable Galunisertib Phase I Actionable In a Phase I trial, two patients with pancreatic cancer demonstrated a best response of stable disease when treated with Galunisertib (LY2157299) (PMID: 26526984; NCT01722825). 26526984
Clinical Trial Phase Therapies Title Recruitment Status
NCT02906397 Phase I Galunisertib A Phase I Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC) Active, not recruiting
NCT02688712 Phase II Capecitabine + Galunisertib Fluorouracil + Galunisertib Galunisertib Fluorouracil Capecitabine ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer Recruiting
NCT02452008 Phase II Galunisertib Enzalutamide Study of TGF-Beta Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Recruiting
NCT02304419 Phase I Galunisertib A Study of Galunisertib on the Immune System in Participants With Cancer Completed
NCT02423343 Phase Ib/II Galunisertib Nivolumab A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma Active, not recruiting
NCT01246986 Phase II Galunisertib + Sorafenib Galunisertib A Study of LY2157299 in Participants With Hepatocellular Carcinoma Active, not recruiting